MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

216.32 4.16

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

207.22

Max

216.6

Galvenie mērījumi
By Trading Economics
Ienākumi	2.9M 56M
Pārdošana	-27M 1B
EPS	2.43
Peļņas marža	5.529
Darbinieki	18,700
EBITDA	-23M 198M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-3.73% downside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.5B 10B
Iepriekšējā atvēršanas cena	212.16
Iepriekšējā slēgšanas cena	216.32

Ziņu noskaņojums

By Acuity

78%

22%

354 / 373 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

117.16 / 144.77 Atbalsts un pretestība

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. janv. 21:14 UTC

Galvenie tirgus virzītāji

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

2026. g. 6. janv. 19:23 UTC

Iegādes, apvienošanās, pārņemšana

OneStream to Go Private Through $6.4 Billion Hg Acquisition

2026. g. 6. janv. 17:41 UTC

Galvenie tirgus virzītāji

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

2026. g. 6. janv. 15:46 UTC

Iegādes, apvienošanās, pārņemšana

Advent International Leads InPost Takeover Offer, Sky News Says

2026. g. 6. janv. 15:37 UTC

Galvenie tirgus virzītāji

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

2026. g. 6. janv. 23:46 UTC

Tirgus saruna

Nikkei May Decline After Hitting Record High -- Market Talk

2026. g. 6. janv. 23:35 UTC

Tirgus saruna

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

2026. g. 6. janv. 23:19 UTC

Tirgus saruna

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

2026. g. 6. janv. 22:53 UTC

Tirgus saruna

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

2026. g. 6. janv. 22:03 UTC

Iegādes, apvienošanās, pārņemšana

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

2026. g. 6. janv. 22:03 UTC

Iegādes, apvienošanās, pārņemšana

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

2026. g. 6. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. janv. 21:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. janv. 21:12 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 6. janv. 21:12 UTC

Tirgus saruna

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

2026. g. 6. janv. 20:59 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Deal Could Be Announced Imminently, Sources Say -- WSJ

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

2026. g. 6. janv. 20:01 UTC

Tirgus saruna

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

2026. g. 6. janv. 19:52 UTC

Tirgus saruna

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

2026. g. 6. janv. 19:46 UTC

Iegādes, apvienošanās, pārņemšana

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

2026. g. 6. janv. 19:08 UTC

Iegādes, apvienošanās, pārņemšana

OneStream to Go Private Through $6.4B Hg Acquisition

2026. g. 6. janv. 18:28 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

2026. g. 6. janv. 17:20 UTC

Tirgus saruna

Peļņas

Financial Services Roundup: Market Talk

2026. g. 6. janv. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2026. g. 6. janv. 15:57 UTC

Tirgus saruna

Crude Futures Ease Back From Early Gains -- Market Talk

2026. g. 6. janv. 15:34 UTC

Tirgus saruna

Peļņas

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

2026. g. 6. janv. 15:27 UTC

Tirgus saruna

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

-3.73% uz leju

Prognoze 12 mēnešiem

Vidējais 200.55 USD -3.73%

Augstākais 225 USD

Zemākais 170 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

354 / 373 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.